Overview Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor Status: Completed Trial end date: 2011-04-01 Target enrollment: Participant gender: Summary To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: PfizerTreatments: Albumin-Bound PaclitaxelAxitinibCapecitabineCarboplatinCisplatinDocetaxelGemcitabinePaclitaxelPemetrexed